Sector News

KKR to invest in Arbor Pharmaceuticals: sources

December 5, 2014
Life sciences
(Reuters) – KKR & Co LP has agreed to acquire a significant minority stake in Arbor Pharmaceuticals LLC, in a deal that values the privately held specialty drugmaker at more than $1 billion, including debt, people familiar with the matter said on Thursday.
 
KKR, a New York-based private equity firm, will own more than a quarter of Arbor Pharmaceuticals under the terms of the deal, the people said, asking not to be identified ahead of an official announcement.
 
KKR declined to comment. An Arbor Pharmaceuticals spokesman did not immediately respond to a request for comment.
 
Based in Atlanta, Georgia, Arbor makes mainly branded prescription drugs for the pediatric, hospital and cardiovascular markets. It offers 16 products and has more than 40 in development, according to its website.
 
Reuters reported in October that Arbor was working with investment bank JPMorgan Chase & Co (JPM.N) on strategic alternatives, including a possible sale.
 
Arbor’s existing shareholders include Chairman Jason Wild, who runs hedge fund firm JW Asset Management LLC; Chief Executive Ed Shutter; investment firm Signet Healthcare Partners LLC; and Allen Chao, co-founder and former chief executive of Watson Pharmaceuticals Inc.
 
Buyout appetite from large pharmaceutical companies and private equity firms has pushed dealmaking in the healthcare sector to record levels this year. Global healthcare volume topped $364.8 billion as the number of announced deals doubled year-to-date, according to Thomson Reuters data.
 
Arbor is the latest minority pharmaceutical investment of KKR this year. In May, KKR took a minority stake in biotherapeutics company Coherus BioSciences Inc. Coherus went public last month last month in an $85 million initial public offering.
 
KKR’s current health care investments also include contract research organization PRA Health Sciences Inc and hospital operator HCA Holdings Inc.
 
(Reporting by Greg Roumeliotis and Olivia Oran in New York; Editing by David Gregorio)

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend